Quantification and localization of oncogenic receptor tyrosine kinase variant transcripts using molecular inversion probes.

about

Quantification and localization of oncogenic receptor tyrosine kinase variant transcripts using molecular inversion probes.

Item

http://www.wikidata.org/entity/Q54979720

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Quantification and localizatio ...... ng molecular inversion probes.

@en

Quantification and localizatio ...... ng molecular inversion probes.

@nl

type

Item

label

Quantification and localizatio ...... ng molecular inversion probes.

@en

Quantification and localizatio ...... ng molecular inversion probes.

@nl

prefLabel

Quantification and localizatio ...... ng molecular inversion probes.

@en

Quantification and localizatio ...... ng molecular inversion probes.

@nl

P1476

Quantification and localizatio ...... ng molecular inversion probes.

@en

P2093

Arvid I Das

http://www.w3.org/2001/XMLSchema#string

Corina N A M van den Heuvel

http://www.w3.org/2001/XMLSchema#string

Femke Simmer

http://www.w3.org/2001/XMLSchema#string

Miguel Angel Molina-Vila

http://www.w3.org/2001/XMLSchema#string

Tessa de Bitter

http://www.w3.org/2001/XMLSchema#string

Thomas Wurdinger

http://www.w3.org/2001/XMLSchema#string

P2860

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine

The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Mechanisms of resistance to EGFR-targeted drugs: lung cancer

Comprehensive molecular profiling of lung adenocarcinoma.

P304

7072

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-018-25328-5

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

William Leenders

P577

2018-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29728634

http://www.w3.org/2001/XMLSchema#string

P932

5935718

http://www.w3.org/2001/XMLSchema#string